Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma
- 5 August 2014
- journal article
- research article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 92 (3), 208-217
- https://doi.org/10.1016/j.critrevonc.2014.07.006
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literatureUrologic Oncology: Seminars and Original Investigations, 2014
- Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patientsInternational Journal of Urology, 2012
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose ReductionJapanese Journal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialThe Lancet Oncology, 2009
- Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinomaExpert Review of Anticancer Therapy, 2009
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Molecular basis of the VHL hereditary cancer syndromeNature Reviews Cancer, 2002